Weekly administration of temsirolimus for heavily pretreated patients with clear cell carcinoma of the ovary: a report of six cases.
Clear cell carcinoma (CCC) of the ovary is well-known to be chemotherapy resistant compared with other histologic subtypes. An inhibitor against the mammalian target of rapamycin, temsirolimus (TEM) has been reported to be effective in renal CCC. Therefore, we investigated the effects of TEM in patients with CCC of the ovary. Six patients with CCC of the ovary who had been heavily pretreated by more than 4 regimens were given TEM: the cycle consisted of weekly TEM (10 mg/m(2)) for 3 weeks followed by 1 week off. The treatment was continued until development of either progressive disease, or unmanageable adverse effects. Response evaluation was based upon the Response Evaluation Criteria in Solid Tumors version 1.0. Adverse effects were analyzed according to Common Terminology Criteria for Adverse Events version 3.0. The median cycle of weekly TEM was 3 (range 2-14). Among five cases in which responses could be evaluated, partial response was observed in one case (20%) and stabilized disease was seen in another case (20%). There were no toxicities greater than grade 3, and no case developed severe toxicity requiring discontinuation of weekly TEM. The patient who showed a partial response obtained a progression-free period of 14 months. In conclusion, weekly TEM shows a potential therapeutic benefit for patients with CCC of the ovary. Further studies including a translational approach are needed to select candidates for whom TEM therapy would be beneficial.
Department of Obstetrics and Gynecology, National Defense Medical College, 3-2 Namiki, Tokorozawa, Saitama, 359-8513, Japan. mastkn@ndmc.ac.jp
Masashi
M
Takano
Yoshihiro
Y
Kikuchi
Kazuya
K
Kudoh
Tomoko
T
Goto
Kenichi
K
Furuya
Ryoko
R
Kikuchi
Tsunekazu
T
Kita
Keiichi
K
Fujiwara
Tanri
T
Shiozawa
Daisuke
D
Aoki
D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy* / Q000473:pathology; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols; D018394:CA-125 Antigen / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D020123:Sirolimus / Q000008:administration & dosage / Q000031:analogs & derivatives*
D000970:Antineoplastic Agents; D018394:CA-125 Antigen; C401859:temsirolimus; D020123:Sirolimus
Int J Gynecol Cancer. 2006 Jan-Feb;16(1):52-6
16445610
Pathol Int. 2009 Jan;59(1):19-27
19121088
Int J Gynecol Cancer. 2008 Sep-Oct;18(5):937-42
18081792
Clin Cancer Res. 2009 Sep 1;15(17):5404-13
19690197
J Clin Oncol. 2003 May 15;21(10 Suppl):187s-193s
12743133
J Clin Oncol. 2004 Jun 15;22(12):2336-47
15136596
Ann Oncol. 2008 Aug;19(8):1387-1392
18385198
Mol Cell Biol. 2002 Oct;22(20):7004-14
12242281
Gynecol Oncol. 2007 Aug;106(2):311-7
17532031
Cancer Res. 2009 May 1;69(9):4036-42
19383911
Cancer. 2000 Jun 1;88(11):2584-9
10861437
Cell. 2000 Oct 13;103(2):253-62
11057898
Br J Cancer. 2006 May 22;94(10):1369-74
16641903
Cancer. 1996 Nov 15;78(10):2157-63
8918409
Gynecol Oncol. 2004 Jul;94(1):197-203
15262142
Clin J Oncol Nurs. 2008 Aug;12(4):639-46
18676330
Gynecol Oncol. 2007 May;105(2):404-8
17292461
Clin Cancer Res. 2003 Aug 1;9(8):2882-6
12912931
Hum Pathol. 2007 Sep;38(9):1310-20
17555795
Cancer Res. 2006 Jun 1;66(11):5549-54
16740688
Gynecol Oncol. 2006 Aug;102(2):285-91
16516283
N Engl J Med. 2007 May 31;356(22):2271-81
17538086
J Clin Oncol. 2004 Mar 1;22(5):909-18
14990647
Gynecol Oncol. 1996 Mar;60(3):412-7
8774649